Exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. Our first commercial product, COMETRIQ® (cabozantinib), received its initial regulatory approval in late 2012. We are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer.

METEOR Results at ECC 2015

Exelixis released positive results for METEOR, the phase 3 pivotal trial of cabozantinib in advanced renal cell carcinoma, at the European Cancer Congress, Sept. 25-29 in Vienna, Austria.

View Press Release
Listen to Webcast
(live Sept. 26, 12:30-2pm EDT; on demand after)


Nov 27 2015 1:00pm EDT
5.47 -0.02